Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind study to evaluate the efficacy and safety of
TRM-201 (rofecoxib) versus Placebo in the treatment of patients with hemophilic arthropathy
(HA) over a 12-week period (Part I) that is followed by a year-long (52 week) open-label
extension (Part II) to further evaluate the safety and maintenance of efficacy of TRM-201.